A New Name for a Global Health Condition: What You Need to Know About PMOS

For decades, a condition affecting 1 in 8 women worldwide has been labeled as Polycystic Ovary Syndrome (PCOS). However, as of May 2026, the medical community has initiated a transition to a more accurate, descriptive name: Polyendocrine Metabolic Ovarian Syndrome (PMOS).

This change, backed by over 50 patient and professional organizations, including the Endocrine Society, aims to address long-standing misconceptions that have historically hindered diagnosis and patient care.

Why the Name Change Matters

The previous name, Polycystic Ovary Syndrome, focused heavily on the presence of cysts on the ovaries. This focus created a clinical and public misunderstanding that the condition was primarily a reproductive issue involving ovarian cysts.

According to Professor Helena Teede, Director of Monash University’s Monash Centre for Health Research & Implementation, the reality is that there is no increase in abnormal cysts on the ovary. For years, the narrow focus on the ovaries led to missed diagnoses and inadequate treatment for a condition that is, in fact, a complex, long-term hormonal or endocrine disorder.

Understanding PMOS

Polyendocrine Metabolic Ovarian Syndrome is characterized by significant fluctuations in hormones. These shifts have wide-reaching impacts on a person’s health, extending far beyond the reproductive system. The condition affects:

• Metabolic Health: Influence on weight and metabolic function.
• Mental Health: Documented impacts on emotional well-being.
• Dermatological Health: Changes in skin, which are common clinical indicators.
• Hormonal Balance: The core endocrine nature of the syndrome.

By shifting the terminology to “Polyendocrine Metabolic,” the medical community acknowledges that the condition is a systemic health issue rather than a localized ovarian one. This shift is intended to improve how the condition is recognized, diagnosed, and managed in clinical settings.

Key Takeaways

• The Name: The condition formerly known as PCOS is now officially Polyendocrine Metabolic Ovarian Syndrome (PMOS).
• The Scope: It is a systemic endocrine and metabolic disorder, not simply a condition defined by ovarian cysts.
• The Impact: The change is designed to reduce the high rates of delayed diagnosis and limited awareness that have historically plagued patients.
• Global Effort: Over 50 organizations collaborated to ensure the new name better reflects the diverse symptoms and long-term health impacts of the syndrome.

Frequently Asked Questions

Why was “Polycystic” misleading?

The term suggested that the primary problem was the presence of cysts on the ovaries. Research has shown that this is not an accurate representation of the condition, and focusing on it caused many patients to receive delayed care for their actual metabolic and endocrine symptoms.

Does this change how the condition is treated?

The name change is a critical step toward improving recognition and care. By correctly identifying the condition as an endocrine and metabolic disorder, healthcare providers are encouraged to look beyond reproductive symptoms and provide more comprehensive, long-term management.

Who led this change?

The process was led by Professor Helena Teede, an endocrinologist at Monash Health and an Endocrine Society member, in collaboration with more than 50 patient and professional organizations dedicated to improving women’s health outcomes.

As the medical community adopts this new terminology, the focus remains on advancing care and ensuring that those affected by PMOS receive the holistic, evidence-based support they need.